J. Griffiths

发表

Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY.

K. Salapa, J. Corren, J. Parnes, 2020, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Effect of ambient levels of smoke and sulphur dioxide on the health of a national sample of 23 year old subjects in 1981.

D. Strachan, H. Anderson, J. Griffiths, 1995, Thorax.

Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.

E. Israel, C. Brightling, G. Colice, 2021, The New England journal of medicine.

Baseline type 2 biomarker levels and response to tezepelumab in severe asthma

K. Salapa, J. Corren, J. Parnes, 2021, Allergy.

Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial Allergy.

C. Ambrose, K. Salapa, J. Corren, 2021, The journal of allergy and clinical immunology. In practice.

Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma: Results from the Phase 3 NAVIGATOR Study

E. Israel, G. Colice, G. Chupp, 2021 .

Tezepelumab decreases matrix remodelling and inflammatory pathways in patients with asthma

S. Sridhar, W. White, Wei Zhao, 2019, Airway pharmacology and treatment.

Tezepelumab normalizes serum interleukin-5 and -13 levels in patients with severe, uncontrolled asthma.

J. Parnes, J. Griffiths, Tuyet-Hang Pham, 2021, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Tezepelumab Treatment Effect on Annualized Rate of Exacerbations by Baseline Biomarkers in Uncontrolled Severe Asthma Patients: Phase 2b PATHWAY Study

J. Corren, J. Parnes, E. Garcia Gil, 2019, B15. IMMUNOTHERAPY FOR LUNG DISEASE.

Exposure-response analysis of tezepelumab in patients with severe asthma to guide phase 3 dose selection

Neang S. Ly, B. Agoram, L. Roskos, 2018, Clinical Problems.

Tezepelumab Reduces Multiple Key Inflammatory Biomarkers in Patients with Severe, Uncontrolled Asthma in the Phase 2b PATHWAY Study

J. Parnes, J. Griffiths, Tuyet-Hang Pham, 2019, B21. SEVERE ASTHMA: CLINICAL AND MECHANISTIC STUDIES.

NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma

G. Colice, A. Menzies-Gow, M. Mo, 2020, Respiratory Research.

Ventilatory function in British adults after asthma or wheezing illness at ages 0-35.

I. D. Johnston, D. Strachan, H. Anderson, 1996, American journal of respiratory and critical care medicine.

Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma

Neang S. Ly, B. Agoram, L. Roskos, 2020, Journal of clinical pharmacology.